You are here

Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Heidelberg, , D-69120 Germany
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Bacterial Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
8 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female subjects, greater than 8 years of age and a weight of more than 35
kilograms.

- Patients with current bacterial infections who have not responded to other available
appropriate antibiotic therapies.

- Patient must give informed consent.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with an expected survival of less than 2 weeks.

- Patients who have been designated as "Do Not Resuscitate".

- Known or suspected hypersensitivity to tigecycline, tetracyclines, or other compounds
related to this class of antibacterial agents.

- Pregnant women or nursing mothers.

NCT00205816
Pfizer
Completed
Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now